Gilead Sciences
GILD
2,331 hedge funds and large institutions have $152B invested in Gilead Sciences in 2026 Q1 according to their latest regulatory filings, with 246 funds opening new positions, 864 increasing their positions, 898 reducing their positions, and 106 closing their positions.
132% more first-time investments, than exits
New positions opened: 246 | Existing positions closed: 106
72% more call options, than puts
Call options by funds: $1.38B | Put options by funds: $804M
18% more funds holding in top 10
Funds holding in top 10: 28 → 33 (+5)
10% more capital invested
Capital invested by funds: $137B → $152B (+$14.3B)
5% more funds holding
Funds holding: 2,226 → 2,331 (+105)
4% less repeat investments, than reductions
Existing positions increased: 864 | Existing positions reduced: 898
2.45% less ownership
Funds ownership: 90.22% → 87.77% (-2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$1.53B |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$886M |
| 3 |
Goldman Sachs
New York
|
+$324M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$288M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$255M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$586M |
| 2 |
Barclays
London,
United Kingdom
|
-$537M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$440M |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
-$433M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$340M |
GILD Hedge Fund Activity: Q1 2026 in Review
2,331 of the 8,208 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q1 2026, worth a combined $152B — up 10% from $137B a quarter earlier.
Buyers outnumbered sellers: 246 funds opened new GILD positions and 106 closed out — a net gain of 140 holders — while 864 added to existing stakes and 898 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $1.53B. The largest seller was BlackRock, cutting an estimated $586M.
- 2,331 institutional investors held Gilead Sciences (GILD) as of Q1 2026, up from 2,226 in Q4 2025.
- Funds reported $152B of Gilead Sciences stock for Q1 2026, up 10% quarter-over-quarter.
- 246 funds opened new Gilead Sciences positions in Q1 2026 and 106 closed out, a net change of +140 holders.
- The largest Gilead Sciences buyer in Q1 2026 was JP Morgan Chase, an estimated $1.53B added.
- The largest Gilead Sciences seller in Q1 2026 was BlackRock, an estimated $586M sold.
Based on aggregated 13F filings for Q1 2026.